Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective

Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective

Loraine Derbyshire, Colin W Thain School of Health, University of Central Lancashire, Preston, United Kingdom Abstract: Chemotherapy induced anemia (CIA) is a frequent complication of anticancer treatment, but often remains untreated. The main presenting symptom of CIA is fatigue, and this can have...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Derbyshire L, Thain CW
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Nursing
RT1-120
Acceso en línea:https://doaj.org/article/751fd7b24a40424aa369ab9f51a30309
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:751fd7b24a40424aa369ab9f51a30309
record_format dspace
spelling oai:doaj.org-article:751fd7b24a40424aa369ab9f51a303092021-12-02T07:01:48ZManaging chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective2230-522Xhttps://doaj.org/article/751fd7b24a40424aa369ab9f51a303092013-11-01T00:00:00Zhttp://www.dovepress.com/managing-chemotherapy-induced-anemia-with-darbepoetin-alfa-and-other-e-a15104https://doaj.org/toc/2230-522XLoraine Derbyshire, Colin W Thain School of Health, University of Central Lancashire, Preston, United Kingdom Abstract: Chemotherapy induced anemia (CIA) is a frequent complication of anticancer treatment, but often remains untreated. The main presenting symptom of CIA is fatigue, and this can have profound implications upon chemotherapy treatment compliance and patients' quality of life (QoL). Nevertheless, a tendency has been seen in both patients and physicians to underestimate the consequences of fatigue. As nurses are taking on greater responsibilities for identifying, monitoring, and in some cases even treating CIA, it is important that they have a clear understanding of the treatment options at their disposal. Erythropoiesis stimulating agents (ESAs) have been available as a tool for the treatment of CIA for many years. However, the vast majority of literature on this topic has been targeted towards physicians. Hence, the purpose of this review is to summarize the key ESA studies, with an emphasis on material that is of interest to the nursing community. Herein we present a brief chronological review of the development of ESAs to illustrate how the currently available treatment options for anemia arose. For conciseness, darbepoetin alfa (DA) has been used as a model to represent all ESAs; however, important findings from studies of other ESAs have also been included for completeness. We also discuss the management of CIA, based on the available literature and our experience of routine clinical practice in the UK. In conclusion, CIA is important in the context of maintaining QoL in patients undergoing chemotherapy and its effective management needs to be considered as part of their holistic care. Available studies show that ESA treatment can decrease fatigue levels and reduce the need for transfusions. ESAs, such as DA, may therefore be an important treatment option for patients with CIA. DA is well tolerated when used according to current recommendations, can be synchronized with chemotherapy cycles, and can also be self-administered. Keywords: chemotherapy-induced anemia, darbepoetin alfa, erythropoiesis stimulating agent, fatigue, quality of life, transfusionDerbyshire LThain CWDove Medical PressarticleNursingRT1-120ENNursing: Research and Reviews, Vol 2013, Iss default, Pp 155-162 (2013)
institution DOAJ
collection DOAJ
language EN
topic Nursing
RT1-120
spellingShingle Nursing
RT1-120
Derbyshire L
Thain CW
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
description Loraine Derbyshire, Colin W Thain School of Health, University of Central Lancashire, Preston, United Kingdom Abstract: Chemotherapy induced anemia (CIA) is a frequent complication of anticancer treatment, but often remains untreated. The main presenting symptom of CIA is fatigue, and this can have profound implications upon chemotherapy treatment compliance and patients' quality of life (QoL). Nevertheless, a tendency has been seen in both patients and physicians to underestimate the consequences of fatigue. As nurses are taking on greater responsibilities for identifying, monitoring, and in some cases even treating CIA, it is important that they have a clear understanding of the treatment options at their disposal. Erythropoiesis stimulating agents (ESAs) have been available as a tool for the treatment of CIA for many years. However, the vast majority of literature on this topic has been targeted towards physicians. Hence, the purpose of this review is to summarize the key ESA studies, with an emphasis on material that is of interest to the nursing community. Herein we present a brief chronological review of the development of ESAs to illustrate how the currently available treatment options for anemia arose. For conciseness, darbepoetin alfa (DA) has been used as a model to represent all ESAs; however, important findings from studies of other ESAs have also been included for completeness. We also discuss the management of CIA, based on the available literature and our experience of routine clinical practice in the UK. In conclusion, CIA is important in the context of maintaining QoL in patients undergoing chemotherapy and its effective management needs to be considered as part of their holistic care. Available studies show that ESA treatment can decrease fatigue levels and reduce the need for transfusions. ESAs, such as DA, may therefore be an important treatment option for patients with CIA. DA is well tolerated when used according to current recommendations, can be synchronized with chemotherapy cycles, and can also be self-administered. Keywords: chemotherapy-induced anemia, darbepoetin alfa, erythropoiesis stimulating agent, fatigue, quality of life, transfusion
format article
author Derbyshire L
Thain CW
author_facet Derbyshire L
Thain CW
author_sort Derbyshire L
title Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
title_short Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
title_full Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
title_fullStr Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
title_full_unstemmed Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
title_sort managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/751fd7b24a40424aa369ab9f51a30309
work_keys_str_mv AT derbyshirel managingchemotherapyinducedanemiawithdarbepoetinalfaandothererythropoiesisstimulatingagentsanurse39sperspective
AT thaincw managingchemotherapyinducedanemiawithdarbepoetinalfaandothererythropoiesisstimulatingagentsanurse39sperspective
_version_ 1718399640012849152

Ejemplares similares